These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26829939)

  • 41. Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor.
    Frye SV
    Curr Top Med Chem; 2006; 6(5):405-21. PubMed ID: 16719800
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia.
    Kang D; Hu C; Fu Y; Wang D
    Clin Invest Med; 2017 Oct; 40(5):E200-E210. PubMed ID: 29061225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostate diseases--role of sex steroids and their inhibitors.
    Welén K; Damber JE
    Best Pract Res Clin Endocrinol Metab; 2011 Apr; 25(2):355-67. PubMed ID: 21397203
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dutasteride for the treatment of prostate-related conditions.
    Slater S; Dumas C; Bubley G
    Expert Opin Drug Saf; 2012 Mar; 11(2):325-30. PubMed ID: 22316171
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 5 alpha-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro.
    Smith CM; Ballard SA; Worman N; Buettner R; Masters JR
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1361-6. PubMed ID: 8636334
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of the steroidal androgen receptor antagonist, Win 49,596, on the prostate and testis of beagle dogs.
    Juniewicz PE; McCarthy M; Lemp BM; Barbolt TA; Shaw C; Hollenbaugh DM; Winneker RC; Reel JR; Batzold FH
    Endocrinology; 1990 May; 126(5):2625-34. PubMed ID: 1691701
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM; Meuleman EJ; van Moorselaar RJ; Bui HN; Blankenstein MA; Heijboer AC; Vis AN
    BJU Int; 2012 Jan; 109(2):183-8. PubMed ID: 21992404
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Dutasteride in the treatment of benign prostatic hyperplasia: an update].
    Chen HJ; Chen YR
    Zhonghua Nan Ke Xue; 2011 Jan; 17(1):63-7. PubMed ID: 21351536
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the α-adrenergic receptor antagonist.
    Qian X; Xu D; Liu H; Lin X; Yu Y; Kang J; Sheng X; Xu J; Zheng S; Xu D; Qi J
    Aging Male; 2017 Dec; 20(4):250-256. PubMed ID: 28787260
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 5α-reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives.
    Al-Mohizea AM; Al-Omar MA; Abdalla MM; Amr AG
    Int J Biol Macromol; 2012 Jan; 50(1):171-9. PubMed ID: 22057085
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
    Bartsch G; Rittmaster RS; Klocker H
    Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advances in the design and discovery of drugs for the treatment of prostatic hyperplasia.
    Kumar R; Malla P; Kumar M
    Expert Opin Drug Discov; 2013 Aug; 8(8):1013-27. PubMed ID: 23662859
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
    Lao K; Sun J; Wang C; Wang Y; You Q; Xiao H; Xiang H
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4212-4217. PubMed ID: 28757062
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chinese Skullcap (Scutellaria baicalensis Georgi) inhibits inflammation and proliferation on benign prostatic hyperplasia in rats.
    Jin BR; Chung KS; Kim HJ; An HJ
    J Ethnopharmacol; 2019 May; 235():481-488. PubMed ID: 30708034
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
    Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
    Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mechanism based representation of the active site of 5 alpha-reductase (5AR).
    Ahmed S; Denison S
    Bioorg Med Chem Lett; 1998 Sep; 8(18):2615-70. PubMed ID: 9873591
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase.
    Frye SV; Haffner CD; Maloney PR; Mook RA; Dorsey GF; Hiner RN; Cribbs CM; Wheeler TN; Ray JA; Andrews RC
    J Med Chem; 1994 Jul; 37(15):2352-60. PubMed ID: 8057283
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Self-organizing molecular field analysis on pregnane derivatives as human steroidal 5alpha-reductase inhibitors.
    Aggarwal S; Thareja S; Bhardwaj TR; Kumar M
    Steroids; 2010 Jun; 75(6):411-8. PubMed ID: 20170668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT; Belgeri MT
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Significance of 5-alpha-reductase inhibitors in therapy of benign prostatic hyperplasia with mild to modern symptoms].
    Wirth MP; Helke C; Froschermaier SE
    Urologe A; 1997 Jan; 36(1):35-9. PubMed ID: 9123679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.